Skip to main content
main-content

Obesity

19-10-2021 | Tirzepatide | News

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

12-10-2021 | Diet | News

DiRECT insights highlight ‘ongoing struggle’ of maintaining weight loss

Many participants of DiRECT found reintroduction of food and subsequent weight-loss maintenance to be more challenging than the 800 calorie total meal replacement phase, the investigators report.

05-10-2021 | EASD 2021 | Conference coverage | News

Semaglutide treatment may reduce systemic inflammation

Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.

04-10-2021 | EASD 2021 | Conference coverage | News

SoliMix trial supports iGlarLixi for type 2 diabetes

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

30-09-2021 | EASD 2021 | Conference coverage | News

Insulin resistance linked to arterial stiffness in type 1 diabetes

Researchers have identified an association between insulin resistance and arterial stiffness among people with type 1 diabetes.

29-09-2021 | EASD 2021 | Conference coverage | News

Intra-organ fat reduction parallels type 2 diabetes remission in lean people

Outwardly lean people who have type 2 diabetes have increased intra-organ fat, reductions in which occur in line with weight loss-induced diabetes remission, say researchers.

17-09-2021 | Metabolic surgery | News

Better cardiovascular outcomes with gastric bypass vs sleeve gastrectomy

Among people with type 2 diabetes and obesity who undergo metabolic surgery, Roux-en-Y gastric bypass is associated with a lower risk for major adverse cardiovascular events than sleeve gastrectomy, suggests a secondary analysis of a cohort study.

16-08-2021 | Liraglutide (obesity) | News

Visceral fat reduction may contribute to liraglutide CV benefits

A randomized trial demonstrates significant reductions in visceral adipose tissue in people with obesity but without diabetes taking the glucagon-like peptide-1 receptor agonist liraglutide.

Image Credits